Despite the various therapeutic strategies used in the treatment of acute febrile neutrophilic dermatoses, interferon-alpha has so far been proposed only as an intralesional monotherapy for cutaneous lesions and has only had partial success. We now describe the treatment of a long-standing, previously drug resistant, case of idiopathic Sweet's syndrome. After an initial successful combined short therapy with systemic interferon-alpha and hydroxyurea, the results were maintained by long-term treatment with interferon-alpha only. To our knowledge, this is the first report showing a clear response to the drug in a patient affected by Sweet's syndrome.
Bianchi, L., Masi, M., Hagman, J., Piemonte, P., Orlandi, A. (1999). Systemic interferon-alpha treatment for idiopathic Sweet's syndrome. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 24(6), 443-445 [10.1046/j.1365-2230.1999.00527.x].
Systemic interferon-alpha treatment for idiopathic Sweet's syndrome
BIANCHI, LUCA;ORLANDI, AUGUSTO
1999-01-01
Abstract
Despite the various therapeutic strategies used in the treatment of acute febrile neutrophilic dermatoses, interferon-alpha has so far been proposed only as an intralesional monotherapy for cutaneous lesions and has only had partial success. We now describe the treatment of a long-standing, previously drug resistant, case of idiopathic Sweet's syndrome. After an initial successful combined short therapy with systemic interferon-alpha and hydroxyurea, the results were maintained by long-term treatment with interferon-alpha only. To our knowledge, this is the first report showing a clear response to the drug in a patient affected by Sweet's syndrome.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
